---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Dostarlimab-gxly - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/dostarlimab-gxly
version: v1
---

# Dostarlimab-gxly - NCI

# Dostarlimab-gxly

Placeholder slot

(dos-TAR-lih-mab)

Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.

US Brand Name(s)

Jemperli

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5&audience=consumer)

## Use in Cancer

Dostarlimab-gxly
is approved to treat adults with:

- **[endometrial cancer](/Common/PopUps/popDefinition.aspx?id=444987&version=Patient&language=English)** that has spread outside the [uterus](/Common/PopUps/popDefinition.aspx?id=46645&version=Patient&language=English) or come back. It is used:
- with [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=Patient&language=English) and [paclitaxel](/Common/PopUps/popDefinition.aspx?id=45258&version=Patient&language=English) and then alone
- alone in patients whose cancer is [mismatch repair deficient](/Common/PopUps/popDefinition.aspx?id=789741&version=Patient&language=English) (dMMR) and got worse during or after treatment with [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English)-based chemotherapy
- **[solid tumors](/Common/PopUps/popDefinition.aspx?id=45301&version=Patient&language=English)** that are dMMR, have spread or come back, and got worse during or after other treatment and cannot be treated with other therapies¹

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that dostarlimab-gxly provides a clinical benefit in these patients.

Dostarlimab-gxly
is also being studied in the treatment of other types of
cancer.

## More About Dostarlimab-gxly

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/780223) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Dostarlimab-gxly](https://medlineplus.gov/druginfo/meds/a621030.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[More Immunotherapy Options Approved for Treating Endometrial Cancer](https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy)

[A Better Biomarker for Cancer Immunotherapy?](https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-mismatch-repair-biomarker)

[Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow](https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-endometrial-cancer-pembrolizumab-dostarlimab)

[Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment](https://www.cancer.gov/news-events/cancer-currents-blog/2023/neoadjuvant-immunotherapy-only-treatment)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why](https://www.cancer.gov/news-events/cancer-currents-blog/2022/immunotherapy-cancer-biomarker-hla-gene)

[Immune Checkpoint Inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Dostarlimab-gxly](https://www.cancer.gov/research/participate/clinical-trials/intervention/C126799) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
